Two Sigma Advisers LP Makes New $171,000 Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)

Two Sigma Advisers LP purchased a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 12,300 shares of the company’s stock, valued at approximately $171,000.

Other large investors also recently modified their holdings of the company. Alta Partners Management Company L.P. bought a new stake in shares of Tyra Biosciences in the 4th quarter worth approximately $56,716,000. Boxer Capital Management LLC purchased a new stake in Tyra Biosciences during the fourth quarter valued at $28,185,000. Farallon Capital Management LLC purchased a new stake in Tyra Biosciences during the fourth quarter valued at $13,914,000. Orbimed Advisors LLC grew its holdings in Tyra Biosciences by 91.3% during the fourth quarter. Orbimed Advisors LLC now owns 1,470,086 shares of the company’s stock valued at $20,434,000 after purchasing an additional 701,448 shares during the period. Finally, Janus Henderson Group PLC grew its holdings in Tyra Biosciences by 63.6% during the fourth quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company’s stock valued at $24,291,000 after purchasing an additional 679,124 shares during the period. 84.14% of the stock is owned by hedge funds and other institutional investors.

Tyra Biosciences Stock Performance

Shares of TYRA opened at $10.55 on Friday. The company has a market capitalization of $560.10 million, a price-to-earnings ratio of -6.55 and a beta of 1.07. Tyra Biosciences, Inc. has a fifty-two week low of $6.42 and a fifty-two week high of $29.60. The firm has a 50-day simple moving average of $9.31 and a 200-day simple moving average of $12.14.

Tyra Biosciences (NASDAQ:TYRA) last released its earnings results on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.49) by $0.02. Equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on TYRA. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Tyra Biosciences in a research report on Monday, March 31st. Piper Sandler began coverage on Tyra Biosciences in a research report on Wednesday, May 21st. They issued an “overweight” rating and a $33.00 price objective for the company. Finally, Wedbush reaffirmed an “outperform” rating and set a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, March 28th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $30.83.

Tyra Biosciences Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.